Edition:
India

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

6,249.00GBp
20 Nov 2018
Change (% chg)

75.00 (+1.21%)
Prev Close
6,174.00
Open
6,219.00
Day's High
6,319.00
Day's Low
6,185.00
Volume
2,648,685
Avg. Vol
1,921,809
52-wk High
6,432.48
52-wk Low
4,544.50

Chart for

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 1.04
Market Cap(Mil.): £65,514.78
Shares Outstanding(Mil.): 1,265.91
Dividend: 68.90
Yield (%): --

Financials

  AZN.L Industry Sector
P/E (TTM): 22.12 31.23 33.59
EPS (TTM): 2.34 -- --
ROI: 7.86 15.57 15.05
ROE: 28.47 16.94 16.62

Key AstraZeneca lung cancer treatment misses study goal

AstraZeneca said on Friday its immunotherapy drug Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares.

16 Nov 2018

Key AstraZeneca lung cancer treatment misses study goal

AstraZeneca said on Friday its immunotherapy drug Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares.

16 Nov 2018

REFILE-UPDATE 1-AstraZeneca's key lung cancer treatment fails main goal in late-stage trial

Nov 16 AstraZeneca's combination of two immunotherapy drugs did not meet the main goal in a closely watched late-stage study for certain type of stage IV lung cancer, the company said on Friday.

16 Nov 2018

AstraZeneca's pivotal lung cancer trial fails main goal in late stage trial

Nov 16 AstraZeneca's combination of two immunotherapy drugs did not meet the main goal in a closely watched late stage study, the company said on Friday.

16 Nov 2018

Sobi buys rights to AstraZeneca infant drug for $1.5 billion upfront

LONDON AstraZeneca has taken another step to refocus on priority drugs by selling U.S. rights to a treatment for infant lung infections to Swedish Orphan Biovitrum for an upfront fee of $1.5 billion.

13 Nov 2018

UPDATE 1-Sobi buys rights to AstraZeneca infant drug for $1.5 bln upfront

* AstraZeneca gets 8 pct stake in Swedish drugmaker (Adds Sobi CEO comment and shares)

13 Nov 2018

AstraZeneca sells infant drug rights to Sobi for $1.5 bln upfront

LONDON, Nov 13 AstraZeneca took another step to refocus its portfolio on priority projects on Tuesday by selling U.S. rights to a treatment for a serious infant lung infection to Swedish Orphan Biovitrum for an upfront fee of $1.5 billion.

13 Nov 2018

AstraZeneca's diabetes drug curbs heart failure, kidney risks

The biggest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca's Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients.

11 Nov 2018

AstraZeneca's diabetes drug curbs heart failure, kidney risks

Nov 10 The biggest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca's Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients.

11 Nov 2018

AstraZeneca sees years of growth as drug sales turn corner

LONDON Strong demand for AstraZeneca's new drugs -- especially those for cancer -- drove a return to sales growth in the third quarter and the drugmaker said it anticipated years of sustained improvement and rising profit margins.

08 Nov 2018

Earnings vs. Estimates